Two of the FTSE 100's biggest defensive names report on Wednesday 28 October, the same day the Chancellor delivers his Budget and the US Federal Reserve sets interest rates.
Company calendars are usually set months in advance, long before anyone knows exactly what else will be happening in the market on a given day. This autumn, that has produced an unusual collision. Unilever (LSE:ULVR) is scheduled to publish its third-quarter trading statement on Wednesday 28 October, and GSK (LSE:GSK) is due to report its third-quarter results on the same day. That date also happens to be Budget day, when Chancellor John Healey presents his first Budget, and the day of the US Federal Reserve's interest rate decision.
For anyone following the FTSE 100, that makes 28 October a day with several competing storylines, each capable of moving prices in different directions.
Two defensive heavyweights
Unilever, the consumer goods group behind a wide range of household and personal care brands, and GSK, the pharmaceuticals and vaccines group, are often grouped together as defensive stocks. The label reflects the idea that demand for everyday essentials and medicines tends to hold up regardless of the economic cycle. Both companies also earn the bulk of their revenue outside the UK, which means their results are driven far more by global trends than by British domestic policy.
That international exposure is one reason why the clash with the Budget may be less awkward than it first appears. A UK Budget typically has its sharpest effect on domestically focused sectors such as banks, housebuilders and retailers. For multinational groups, the more direct channels tend to be sterling, the wider gilt market and any changes to corporate taxation that affect UK-based operations.
Why the timing still matters
Even so, results released on a crowded day can be harder to read. A solid set of numbers might be overshadowed by a sharp move in gilt yields after the Budget, or by a reaction to the Fed's decision later in the day UK time. Equally, a disappointing update could be masked by a broader rally. For anyone trying to work out how the market has judged a company's results, the noise from other events can make the signal harder to pick out.
The wider backdrop going into Budget day is already tense. The UK 10-year gilt yield closed at 5.42% on Friday 9 October, having touched 5.53% intraday the previous day, the highest since July 2007. The 30-year gilt reached 6.05% intraday on Thursday 8 October, its highest since early 1998. One estimate suggests the Budget could add £15bn of borrowing in each of 2026/27 and 2027/28. If the Budget increases borrowing by more or less than the market expects, gilt yields could react, and with them the valuations of companies whose shares are often compared to bonds for their steady income.
For dollar and euro earners like Unilever and GSK, sterling matters. A weaker pound tends to lift the value of overseas profits when translated back into pounds, while a firmer pound reduces it. On Friday 9 October, the ECB reference rate put sterling at 1.3220 against the dollar and 1.1798 against the euro, both slightly up on the week.
A Budget that unsettles investors in UK government debt could weigh on the pound, while a Fed decision that surprises markets could move the dollar. Either could change the way trading figures released that morning are interpreted, especially if the companies comment on currency effects.
A busy fortnight for consumer and healthcare names
Unilever and GSK are part of a wider cluster of results from large defensive companies. Reckitt (LSE:RKT) reports its third-quarter figures on Tuesday 27 October, the day before. AstraZeneca (LSE:AZN) follows with its third-quarter results on Friday 30 October. Taken together, the four companies offer a broad read on consumer staples and healthcare within the FTSE 100 in the space of four trading days.
Unilever has another event shortly afterwards: an investor event in New York on Wednesday 4 November. Investor events are often used to set out strategy in more depth than a quarterly update allows, so the trading statement on 28 October may be read partly as a prelude.
Specific forecasts for either company's quarter have not been widely set out. What can be said is that the main themes for consumer goods groups in recent years have included pricing, volumes and input costs, while for pharmaceuticals the focus is usually on product pipelines, sales of key medicines and pricing pressures in major markets.
The index heads into the second half of October after a mixed run. It closed Friday 9 October at 10,552.05, up 0.86% for the week, after falling 2.2% the week before. It remains about 4.0% below its all-time high of 10,991.07, set in July 2026. The Bank of England, meanwhile, holds Bank Rate at 3.75%, with its next decision due on Thursday 5 November, a week after the Budget.
Key dates to watch
- Tuesday 27 October: Reckitt and HSBC (LSE:HSBA) third-quarter results.
- Wednesday 28 October: UK Budget from Chancellor John Healey; US Federal Reserve decision.
- Wednesday 28 October: Unilever third-quarter trading statement and GSK third-quarter results.
- Friday 30 October: AstraZeneca third-quarter results.
- Wednesday 4 November: Unilever investor event in New York.
- Thursday 5 November: Bank of England rate decision and Monetary Policy Report.
The bottom line
Wednesday 28 October brings together a UK Budget, a Fed decision and results from two of the FTSE 100's largest defensive companies. Because Unilever and GSK earn most of their money abroad, the Budget itself may matter less to their fundamentals than to the gilt market and sterling, which in turn can colour how their numbers are received.
For those watching the index, the more useful exercise may be to separate the company-specific messages from the day's macro noise. That can take a few sessions to become clear, especially with Reckitt the day before, AstraZeneca two days later and a Bank of England decision the following week.






Please wait processing your request...